Biodegradable orthopedic implants are intended to stabilize bone for a defined healing period and then gradually degrade or absorb in the body. The aim is to reduce the long-term presence of permanent hardware without compromising fixation while the fracture or repair site is still vulnerable. In current fracture fixation and bone repair discussions, the key questions are practical: where are these devices clinically appropriate, how do polymer, ceramic-composite, and magnesium-based systems differ, and what limits broader use?
For now, the strongest near-term role is in selected temporary fixation applications, not high-load joint replacement. Recent regulatory and standards activity, including FDA classification of absorbable metallic bone fixation fasteners and ISO guidance for absorbable metallic implants, shows a more structured pathway for the category. At the same time, developers still need rigorous evidence on degradation, strength retention, biocompatibility, revision scenarios, and labeling. (public-inspection.federalregister.gov)
For more coverage of implant materials and fixation technologies, visit the Implants section.
What biodegradable orthopedic implants are meant to do
In orthopedic use, “biodegradable,” “bioabsorbable,” “bioresorbable,” and “absorbable” are often used in overlapping ways. The practical goal is similar: the implant provides temporary mechanical support and is then broken down, absorbed, metabolized, or replaced by tissue over time. ISO terminology describes degradation as physical, chemical, or metabolic decomposition, while absorbable implant guidance emphasizes the need to understand both the material and its degradation products. (iso.org)
This separates biodegradable orthopedic implants from conventional stainless steel, cobalt-chromium, or titanium devices, which are designed to remain in the body unless symptoms or complications justify removal. A biodegradable fixation device has to solve two problems at the same time. It must be strong enough for the anatomical site and expected healing timeline, and it must lose strength and mass at a rate that does not compromise fixation, trigger an unacceptable tissue response, or make revision surgery more difficult.
The concept is especially relevant for screws, pins, plates, interference screws, suture anchors, bone void fillers, and scaffold-like devices. It is less straightforward for total hip, knee, or other joint replacement components, where long-term wear resistance and sustained load-bearing performance are still critical requirements.
The main material families
Current biodegradable orthopedic implants fall into three broad material groups: absorbable polymers, absorbable metals, and ceramic or composite systems. Each group has a different degradation mechanism, mechanical profile, and risk pattern.
| Material family | Typical examples | Common orthopedic role | Main advantage | Main limitation |
|---|---|---|---|---|
| Absorbable polymers | PLA, PLLA, PGA, PLGA, PCL, polydioxanone | Screws, pins, anchors, plates in selected indications | Long clinical history and tunable degradation | Lower stiffness and strength than metals; inflammatory reaction risk in some older systems |
| Absorbable metals | Magnesium, magnesium alloys, zinc-based and iron-based systems under study | Temporary fixation screws, pins, wires, and developing plate concepts | Metal-like handling with potential bone-compatible stiffness | Corrosion control, gas evolution, and site-specific degradation variability |
| Ceramics and composites | Hydroxyapatite, tricalcium phosphate, bioactive glass, polymer-ceramic blends | Bone void filling, osteoconductive scaffolds, reinforced fixation materials | Bone-conductive behavior and support for remodeling | Brittleness or limited load-bearing capacity when used alone |
Polymers remain important because standards and manufacturing pathways are more established. ISO 13781:2017 covers in vitro degradation testing for poly(lactide)-based homopolymers, copolymers, and blends used in surgical implants. ASTM F2902 provides a general assessment guide for absorbable polymeric implants, including chemical, physical, mechanical, biocompatibility, and preclinical considerations. (iso.org)
Magnesium-based implants are attracting particular attention because magnesium alloys can be closer to bone in stiffness than traditional dense metals while still degrading in the body. Recent reviews describe magnesium as the most clinically advanced biodegradable metallic system in orthopedics compared with zinc and iron. The same reviews also emphasize that corrosion rate, hydrogen evolution, and load-bearing reliability remain major engineering and clinical questions. (doi.org)
Why surgeons and device developers are interested
The first appeal of biodegradable orthopedic implants is the possibility of avoiding a planned or unplanned second operation for hardware removal. Removal is not always needed after titanium or stainless steel fixation, but it may be considered when hardware is painful, prominent, infected, interfering with growth, or problematic near tendons and soft tissue. In pediatric and young adult patients, avoiding permanent hardware can be especially attractive, although evidence still has to be judged by indication.
The second appeal is mechanical matching. If an implant is much stiffer than the surrounding bone, it can change load transfer. Magnesium alloys are not identical to bone, but their modulus is generally closer to cortical bone than stainless steel or conventional titanium alloys. This is one reason magnesium has become a focus for temporary fixation devices, rather than only a biodegradable substitute for older polymer screws. (pmc.ncbi.nlm.nih.gov)
The third appeal is imaging and follow-up. Permanent metallic hardware can create artifacts in some imaging contexts, while absorbable devices may reduce long-term interference after degradation. This benefit depends on the material, anatomy, imaging modality, and stage of degradation, so it should not be assumed for every device.
There is also a health-system argument. Fewer removal procedures could mean less surgical burden and lower use of operating room resources. That economic case is credible only when the implant performs as intended, avoids new complications, and is supported by evidence in the relevant indication.
What the clinical and regulatory evidence currently shows
The evidence base is mixed, but it is becoming more mature. Polymer-based bioabsorbable implants have decades of orthopedic use, although earlier generations were associated in some settings with foreign-body reactions, cysts, or fixation concerns. Newer composite polymers and magnesium-based devices are being studied to address these weaknesses.
For magnesium, clinical evidence is strongest in selected foot, ankle, and fracture fixation indications, not across all orthopedic surgery. A PubMed-indexed systematic review and meta-analysis of magnesium or magnesium-alloy implants reported eight clinical studies involving 468 patients, including 230 magnesium screws and 213 titanium screws. The review concluded that magnesium-based absorbable implants were clinically useful and biologically acceptable in the studied bone surgery settings, while also showing the limited size and scope of available trials. (pubmed.ncbi.nlm.nih.gov)
A 2025 systematic review of bioabsorbable magnesium-based materials reported a lower revision-surgery rate in the magnesium group than in the titanium comparator group across included studies. Those results should still be read with caution because anatomical sites, patient populations, device designs, and follow-up periods vary. (pubmed.ncbi.nlm.nih.gov)
The regulatory picture in the United States became more concrete after FDA granted De Novo authorization on March 29, 2023, for the RemeOs Screw LAG Solid and created the generic type “absorbable metallic bone fixation fastener.” The Federal Register final order, effective June 5, 2026, classified this generic device type as class II with special controls. FDA identified risks including loss of fixation from premature absorption, device breakage, galvanic corrosion, device aging, adverse tissue reaction, infection, and difficulties with revision surgery due to absorption. (accessdata.fda.gov)
This is significant, but it should not be overread. A class II pathway does not mean every absorbable metal screw is suitable for every fracture. It means devices of that type must meet general and special controls. Individual products still need evidence for their intended use, material, design, absorption profile, shelf life, sterilization, and labeling.
The core challenge is matching degradation to healing
Every biodegradable implant faces the same central design problem: healing is biological and variable, while degradation is material-driven and environment-dependent. A fixation screw that weakens too quickly can lose purchase before union. A device that degrades too slowly may behave more like permanent hardware and reduce the intended benefit. A material that releases acidic polymer byproducts, corrosion products, or gas too quickly may create local tissue concerns.
For absorbable polymers, hydrolysis is a major degradation route for many commonly used materials. Polymer chemistry, crystallinity, molecular weight, geometry, sterilization, processing, and local fluid exposure can all affect the degradation timeline. Standards such as ISO 13781 and ASTM F2902 exist because degradation cannot be treated as a simple marketing claim; it has to be characterized through physical, mechanical, chemical, and biological testing. (iso.org)
For magnesium-based implants, degradation is corrosion-related. The advantage is that magnesium can gradually dissolve in the physiological environment. The risk is that rapid corrosion may produce hydrogen gas pockets, early mechanical weakening, or local pH changes. Alloying, surface treatment, heat treatment, coatings, and device geometry are all being studied to slow and stabilize degradation. Reviews published in 2025 and 2026 consistently identify controlled corrosion and reliable long-term mechanical support as decisive barriers to broader use. (sciencedirect.com)
The practical takeaway is that “biodegradable” is not automatically safer or more advanced than permanent fixation. The right comparison is indication by indication. Fracture type, load, fixation demand, patient age, bone quality, soft tissue environment, infection risk, surgeon familiarity, and revision options all matter.
Where biodegradable implants may fit best
The most credible near-term uses are temporary fixation scenarios where the required support period is limited and where avoiding long-term hardware has a clear rationale. Examples include selected malleolar, metatarsal, osteotomy, pediatric, hand, foot, ankle, and sports-related fixation applications, depending on the specific device clearance or approval in each market.
In lower-load or small-bone fixation, absorbable polymers may be sufficient. In situations requiring stronger fixation with bone-like mechanical behavior, magnesium-based systems may offer advantages if degradation is controlled. In bone defect management, ceramics and bioactive composites may be more relevant as osteoconductive scaffolds than as primary load-bearing fixation.
Higher-load long bone fixation, complex periarticular fractures, osteoporotic bone, infected fields, revision surgery, and patients with impaired healing remain more demanding settings. In these cases, biodegradable implants should not be treated as interchangeable with titanium or stainless steel unless robust clinical and mechanical evidence supports that use.
How to evaluate claims about biodegradable orthopedic implants
Because the category is developing quickly, claims should be evaluated against the intended use rather than the material label alone. A practical checklist includes:
- Indication match: Is the evidence for the same anatomical site, fracture pattern, and patient population?
- Mechanical testing: Does the device retain enough strength through the expected healing window?
- Degradation profile: Is absorption characterized to completion, not just early follow-up?
- Biocompatibility: Are material byproducts, corrosion products, and local tissue reactions evaluated?
- Imaging and follow-up: Can surgeons monitor healing and detect complications reliably?
- Revision planning: If fixation fails or infection occurs, does degradation make revision easier or harder?
- Regulatory status: Is the device cleared, authorized, CE-marked, or investigational for the intended use and region?
The FDA’s special controls for absorbable metallic bone fixation fasteners reflect many of these same issues. They require clinical data, non-clinical performance testing, shelf-life testing, biocompatibility evaluation, sterilization validation, pyrogenicity testing, and labeling to mitigate known risks. (public-inspection.federalregister.gov)
Frequently asked questions
Are biodegradable orthopedic implants already used in patients?
Yes. Absorbable polymer devices have been used in orthopedic surgery for many years, and magnesium-based absorbable fixation devices have entered clinical use in selected indications and regions. Use depends on the specific product, regulatory status, surgeon judgment, and patient factors.
Do biodegradable implants eliminate the need for follow-up surgery?
They may reduce the need for routine hardware removal in appropriate cases, but they do not eliminate the possibility of revision surgery. Nonunion, infection, implant breakage, early degradation, or local tissue response can still require intervention.
Are magnesium implants better than polymer implants?
Not universally. Magnesium implants may offer higher stiffness and metal-like handling for some fixation tasks, while polymers may be suitable for lower-load applications and have a longer clinical history. The better choice depends on the indication, design, degradation behavior, and available clinical evidence.
Can biodegradable implants replace titanium implants?
In selected temporary fixation indications, they may be an alternative. For many high-load or long-term orthopedic applications, titanium and other permanent materials remain standard because of their established strength, fatigue performance, and clinical history.
What is the main risk with biodegradable orthopedic implants?
The main risk is a mismatch between mechanical support and biological healing. If an implant weakens or degrades before the bone has healed, fixation can fail. If degradation products cause local reaction, pain, gas formation, or inflammation, the intended benefit may be reduced.
Outlook
Biodegradable orthopedic implants are not one technology. They are a family of materials with different strengths, degradation pathways, and trade-offs. The priority is not simply faster absorption; it is predictable absorption that matches healing, maintains fixation long enough, and leaves no clinically significant byproduct burden. Magnesium-based systems are likely to remain a major development area because they combine absorbability with more metal-like mechanical performance. Advanced polymers and composites will continue to serve lower-load fixation, anchor, and scaffold roles.
For clinicians, developers, and industry observers, the key question is no longer whether biodegradable orthopedic implants are promising. It is where the evidence is strong enough for a specific use, and where permanent fixation remains the safer, better-supported option.